Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans
Open Access
- 23 April 2003
- journal article
- clinical trial
- Published by Springer Nature in Psychopharmacology
- Vol. 168 (4) , 446-454
- https://doi.org/10.1007/s00213-003-1444-8
Abstract
LY354740, a structural analogue of glutamate that shows specificity at the mGluR2/3 receptor, has anxiolytic effects in animal models.Keywords
This publication has 37 references indexed in Scilit:
- Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats.Behavioral Neuroscience, 2002
- Interactions between LY354740, a Group II metabotropic agonist and the GABAA-benzodiazepine receptor complex in the rat elevated plus-mazeJournal of Psychopharmacology, 2001
- Darkness facilitates the acoustic startle reflex in humansBiological Psychiatry, 1997
- Diazepam blocks fear-potentiated startle in humans.Journal of Abnormal Psychology, 1996
- Novel functions for subtypes of metabotropic glutamate receptorsNeurochemistry International, 1994
- Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startleBehavioral and Neural Biology, 1993
- The Role of the Amygdala in Fear and AnxietyAnnual Review of Neuroscience, 1992
- Fear‐Potentiated Startle in Humans: Effects of Anticipatory Anxiety on the Acoustic Blink ReflexPsychophysiology, 1991
- Development and validation of brief measures of positive and negative affect: The PANAS scales.Journal of Personality and Social Psychology, 1988
- Lesions of the amygdala, but not of the cerebellum or red nucleus, block conditioned fear as measured with the potentiated startle paradigm.Behavioral Neuroscience, 1986